Genomic Valley Biotech share news, announcements and annual reports
BSE: 539206Pharmaceuticals & BiotechnologySmall Cap
GENOMIC VALLEY BIOTECH LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2015
Last close ₹48.10up ₹2.29 (5.00%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹45.81.
30 Oct: open ₹48.10, high ₹48.10, low ₹48.00
52-week range of traded prices to 30 Oct 2026
₹20.10Low, 29 Jan 2026₹48.10High, 30 Oct 2026
- Under BSE's graded surveillance, stage I, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15 Cr4,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.74
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 9,359
Genomic Valley Biotech routine notices
202 filed, newest first. Page 4 of 5.
Jul 2019
31 Jul · Routine
31 Jul · Routine
30 Jul · Routine
24 Jul · Routine
5 Jul · Routine
May 2019
31 May · Routine
23 May · Routine
Feb 2019
14 Feb · Routine
4 Feb · Routine
Jan 2019
23 Jan · Routine
Nov 2018
Oct 2018
30 Oct · Routine
Sep 2018
6 Sep · Routine
Aug 2018
11 Aug · Routine
Jul 2018
30 Jul · Routine
May 2018
31 May · Routine
21 May · Routine
Feb 2018
5 Feb · Routine
Jan 2018
19 Jan · Routine
Nov 2017
15 Nov · Routine
Sep 2017
14 Sep · Routine
6 Sep · Routine
5 Sep · Routine
4 Sep · Routine
Aug 2017
May 2017
Feb 2017
Nov 2016
Sep 2016
Jul 2016
May 2016
23 May · Routine
Meeting of the Board of Directors of the Company is scheduled on held on May 30, 2016,inter alia, to consider and approve the Audited ....
Jan 2016
4 Jan · Routine
Meeting of the Board of Directors of the Company is scheduled on held on January 11, 2016, inter alia, to consider and approve the Un-Audited ....